Heterotopic ossification after total hip arthroplasty: When is development completed?
Aged
Anti-Inflammatory Agents, Non-Steroidal
/ administration & dosage
Arthroplasty, Replacement, Hip
/ adverse effects
Cyclooxygenase 2 Inhibitors
/ administration & dosage
Etoricoxib
/ administration & dosage
Female
Humans
Male
Middle Aged
Ossification, Heterotopic
/ complications
Postoperative Complications
/ diagnostic imaging
Prospective Studies
Brooker
Heterotopic ossification
Ossification prophylaxis
Total hip arthroplasty
Journal
Journal of orthopaedic surgery and research
ISSN: 1749-799X
Titre abrégé: J Orthop Surg Res
Pays: England
ID NLM: 101265112
Informations de publication
Date de publication:
05 Mar 2022
05 Mar 2022
Historique:
received:
21
10
2021
accepted:
21
01
2022
entrez:
6
3
2022
pubmed:
7
3
2022
medline:
23
3
2022
Statut:
epublish
Résumé
Heterotopic ossifications (HO) are a common complication after total hip arthroplasty (THA). Nonsteroidal anti-inflammatory drugs have proven to reduce the occurrence of HO. It is still unclear when the formation of HO is finished. Aim of our study was to answer this question. In a prospective study, the occurrence of periarticular HO was checked during the follow-up (FU) examinations. In total, 75 consecutive patients who underwent THA were included. To ensure a high follow-up rate, only patients with a life expectancy of at least 10 years were included. A medical ossification prophylaxis with mostly etoricoxib (90 mg once daily) was administered. Follow-up examinations were performed at 3 months, 1 year, 3, 5, and 10 years postoperatively. Each time, a clinical and radiological examination was carried out. The HO was graded according to Brooker's method. Low-grade HO classified by Brooker grade I and II occurred significantly more frequent than HO grade III. In patients with present HO, a possible increase in Brooker stage could further be observed within 3 years postoperatively. After 3 years, the formation of HO was completed in all patients. Three years after THA, the formation of HO is complete. After more than 3 years postoperatively, if HO occurs or increases, other triggering causes such as new trauma, periarticular infection, or implant loosening should be considered.
Sections du résumé
BACKGROUND
BACKGROUND
Heterotopic ossifications (HO) are a common complication after total hip arthroplasty (THA). Nonsteroidal anti-inflammatory drugs have proven to reduce the occurrence of HO. It is still unclear when the formation of HO is finished. Aim of our study was to answer this question.
METHODS
METHODS
In a prospective study, the occurrence of periarticular HO was checked during the follow-up (FU) examinations. In total, 75 consecutive patients who underwent THA were included. To ensure a high follow-up rate, only patients with a life expectancy of at least 10 years were included. A medical ossification prophylaxis with mostly etoricoxib (90 mg once daily) was administered. Follow-up examinations were performed at 3 months, 1 year, 3, 5, and 10 years postoperatively. Each time, a clinical and radiological examination was carried out. The HO was graded according to Brooker's method.
RESULTS
RESULTS
Low-grade HO classified by Brooker grade I and II occurred significantly more frequent than HO grade III. In patients with present HO, a possible increase in Brooker stage could further be observed within 3 years postoperatively. After 3 years, the formation of HO was completed in all patients.
CONCLUSION
CONCLUSIONS
Three years after THA, the formation of HO is complete. After more than 3 years postoperatively, if HO occurs or increases, other triggering causes such as new trauma, periarticular infection, or implant loosening should be considered.
Identifiants
pubmed: 35248082
doi: 10.1186/s13018-022-02959-z
pii: 10.1186/s13018-022-02959-z
pmc: PMC8898402
doi:
Substances chimiques
Anti-Inflammatory Agents, Non-Steroidal
0
Cyclooxygenase 2 Inhibitors
0
Etoricoxib
WRX4NFY03R
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
147Informations de copyright
© 2022. The Author(s).
Références
Zhu Y, Zhang F, Chen W, Zhang Q, Liu S, Zhang Y. Incidence and risk factors for heterotopic ossification after total hip arthroplasty: a meta-analysis. Arch Orthop Trauma Surg. 2015;135:1307–14.
doi: 10.1007/s00402-015-2277-8
Eggli S, Woo A. Risk factors for heterotopic ossification in total hip arthroplasty. Arch Orthop Trauma Surg. 2001;121:531–5.
doi: 10.1007/s004020100287
Legosz P, Otworowski M, Sibilska A, Starszak K, Kotrych D, Kwapisz A, Synder M. Heterotopic ossification: a challenging complication of total hip arthroplasty: risk factors, diagnosis, prophylaxis, and treatment. Biomed Res Int. 2019;2019:1–8.
doi: 10.1155/2019/3860142
Rüdiger HA, Dittrich M, Robinson J, Mansour T, Schwab T, Stadelmann VA, Leunig M. The impact of heterotopic ossification on self-reported outcomes after total hip arthroplasty using the direct anterior approach. J Bone Jt Surg Am. 2020;102(Suppl 2):91–8.
doi: 10.2106/JBJS.20.00071
Van Erp JHJ, Massier JRA, Truijen S, Bekkers JEJ, Snijders TE, de Gast A. Heterotopic ossification in primary total hip arthroplasty using the posterolateral compared to the direct lateral approach. Arch Orthop Trauma Surg. 2021. https://doi.org/10.1007/s00402-021-03783-6 .
doi: 10.1007/s00402-021-03783-6
pubmed: 34101017
pmcid: 9110501
Alijanipour P, Patel RP, Naik TU, Parvizi J. Heterotopic ossification in primary total hip arthroplasty using the direct anterior versus direct lateral approach. J Arthroplasty. 2017;32:1323–7.
doi: 10.1016/j.arth.2016.11.030
Eggli S, Rodriguez J, Ganz R. Heterotopic ossification in total hip arthroplasty: the significance for clinical outcome. Acta Orthop Belg. 2000;66:174–80.
pubmed: 10842879
Ahrengart L. Periarticular heterotopic ossification after total hip arthroplasty. Risk factors and consequences. Clin Orthop Rel Res. 1991;263:49–58.
doi: 10.1097/00003086-199102000-00005
Cai L, Wang Z, Luo X, She W, Zhang H. Optimal strategies for the prevention of heterotopic ossification after total hip arthroplasty: a network meta-analysis. Int J Surg. 2019;62:74–85.
doi: 10.1016/j.ijsu.2018.12.011
Migliorini F, Trivellas A, Eschweiler J, Driessen A, Tingart M, Maffulli N. NSAIDs for prophylaxis for heterotopic ossification after total hip arthroplasty: a Bayesian network meta-analysis. Calc Tissue Int. 2021;108:196–206.
doi: 10.1007/s00223-020-00763-7
Brooker AF, Bowerman JW, Robinson RA, Riley LH. Ectopic ossification following total hip replacement. Incidence and method of classification. J Bone Jt Surg Am. 1973;55:1629–32.
doi: 10.2106/00004623-197355080-00006
Winkler S, Springorum HR, Vaitl T, Handel M, Barta S, Kehl V, Craiovan B, Grifka J. Comparative clinical study of the prophylaxis of heterotopic ossifications after total hip arthroplasty using etoricoxib or diclofenac. Int Orthop. 2016;40:673–80.
doi: 10.1007/s00264-015-3077-z
Oberberg S, Nottenkämper N, Heukamp M, Krapp J, Willburger RE. Etoricoxib is safe and effective in preventing heterotopic ossification after primary total hip arthroplasty. J Orthop Surg Res. 2021;16:163–8.
doi: 10.1186/s13018-021-02297-6